Chen Chung-Shih, Huang Eng-Yen
Departments of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung City 833, Taiwan.
School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung City 804, Taiwan.
Cancers (Basel). 2023 Jun 2;15(11):3034. doi: 10.3390/cancers15113034.
To stratify patients according to tumor marker and histology and compare the survival outcome between radical hysterectomy (RH) and primary concurrent chemoradiotherapy (CCRT) in bulky IB and IIA cervical cancer.
A total of 442 patients with cervical cancer were enrolled in the Chang Gung Research Database from January 2002 to December 2017. Patients with squamous cell carcinoma (SCC) and carcinoembryonic antigen (CEA) ≥10 ng/mL, adenocarcinoma (AC), or adenosquamous carcinoma (ASC) were stratified into the high-risk (HR) group. The others were classified into the low-risk (LR) group. We compared oncology outcomes between RH and CCRT in each group.
In the LR group, 5-year overall survival (OS) and recurrence-free survival (RFS) were 85.9% vs. 85.4% ( = 0.315) and 83.6% vs. 82.5% ( = 0.558) in women treated with RH ( = 99) vs. CCRT ( = 179), respectively. In the HR group, the 5-year OS and RFS were 83.2% vs. 73.3% ( = 0.164) and 75.2% vs. 59.6% ( < 0.036) in patients treated with RH ( = 128) vs. CCRT ( = 36), respectively. Regarding recurrence, locoregional recurrence (LRR) (8.1% vs. 8.6%, = 0.812) and distant metastases (DM) (17.8% vs. 21%, = 0.609) were similar between RH and CCRT in the LR group. However, lower LRR (11.6% vs. 26.3%, = 0.023) but equivalent DM (17.8% vs. 21%, = 0.609) were found for women undergoing RH compared with CCRT in the HR group.
There were similar survival and recurrence rates between both treatment modalities in low-risk patients. Meanwhile, primary surgery with or without adjuvant radiation provides better RFS and local control in women with high-risk features. Further prospective studies are needed to confirm these findings.
根据肿瘤标志物和组织学对患者进行分层,并比较在大块ⅠB期和ⅡA期宫颈癌中根治性子宫切除术(RH)和同期放化疗(CCRT)之间的生存结果。
2002年1月至2017年12月期间,共有442例宫颈癌患者纳入长庚研究数据库。鳞状细胞癌(SCC)且癌胚抗原(CEA)≥10 ng/mL、腺癌(AC)或腺鳞癌(ASC)患者被分层到高危(HR)组。其他患者被分类到低危(LR)组。我们比较了每组中RH和CCRT之间的肿瘤学结果。
在LR组中,接受RH(n = 99)和CCRT(n = 179)治疗的女性的5年总生存率(OS)分别为85.9%和85.4%(P = 0.315),无复发生存率(RFS)分别为83.6%和82.5%(P = 0.558)。在HR组中,接受RH(n = 128)和CCRT(n = 36)治疗的患者的5年OS分别为83.2%和73.3%(P = 0.164),RFS分别为75.2%和59.6%(P < 0.036)。关于复发,LR组中RH和CCRT之间的局部区域复发(LRR)(8.1%对8.6%,P = 0.812)和远处转移(DM)(17.8%对21%,P = 0.609)相似。然而,HR组中接受RH治疗的女性与接受CCRT治疗的女性相比,LRR较低(11.6%对26.3%,P = 0.023),但DM相当(17.8%对21%,P = 0.609)。
低危患者中两种治疗方式的生存率和复发率相似。同时,有或没有辅助放疗的初次手术在具有高危特征的女性中提供了更好的RFS和局部控制。需要进一步的前瞻性研究来证实这些发现。